二线化疗后切除结直肠癌肝转移是否值得:LiverMetSurvey对6415例患者的分析
该研究基于前瞻性国际队列,比较一线与二线术前化疗后行结直肠癌肝转移切除患者的结局。二线组与一线组总生存无差异,但二线组无病生存期更短;在初始不可切除患者中两组总生存或无病生存期无统计学差异。
要点
- 二线术前化疗后切除结直肠癌肝转移的总生存与一线化疗后切除相似。
- 二线组无病生存期较一线组更短,中位17.2个月 vs 19.4个月。
- 初始不可切除患者中,一线与二线术前化疗的总生存或无病生存期无统计学差异。
核心结论
- 经肿瘤外科有利选择后,二线术前化疗后切除结直肠癌肝转移可获得与一线化疗后切除相似的总生存。
- 对于初始不可切除患者,一线与二线术前化疗的总生存或无病生存期具有可比性。
- 一线化疗失败后不应拒绝手术。
研究设计与样本
- 前瞻性国际队列研究,纳入2005年1月至2013年6月连续患者。
- 5624例接受1线术前化疗(1组),791例接受2线术前化疗(2组),随后行结直肠癌肝转移切除。
- 分析生存与预后因素。
主要发现
- 中位随访30.1个月,自结直肠癌肝转移诊断起中位、3年、5年总生存:2组分别为58.6个月、76%、49%,1组分别为58.9个月、71%、49%,P=0.32。
- 肝切除后无病生存期2组更短:中位17.2个月、3年27%、5年15%,1组分别为19.4个月、32%、23%,P=0.001。
- 初始不可切除患者中,1组与2组的总生存或无病生存期无统计学差异。
- 2组总生存较差的独立预测因素包括:原发淋巴结阳性、肝外转移、二线治疗中肿瘤进展、R2切除、每年肝切除例数<50。
- 无病生存期较短的预测因素包括:原发淋巴结阳性、同时性转移、双侧转移。
关键数值与推荐
- 2组总生存较差的独立预测因素:原发淋巴结阳性、肝外转移、二线治疗中肿瘤进展、R2切除、每年肝切除例数<50。
- 无病生存期较短的预测因素:原发淋巴结阳性、同时性转移、双侧转移。
- 在2组中,初始不可切除对总生存或无病生存期无影响。
临床怎么用
- 经肿瘤外科有利选择后,二线术前化疗后行结直肠癌肝转移切除可获得与一线化疗后切除相似的总生存。
- 对于初始不可切除患者,一线与二线术前化疗的总生存或无病生存期具有可比性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patient outcome after resection of colorectal liver metastases (CLM) following second-line preoperative chemotherapy (PCT) performed for insufficient response or toxicity of the first-line, is little known and has here been compared to the outcome following first-line. PATIENTS AND METHODS: From January 2005 to June 2013, 5624 and 791 consecutive patients of a prospective international cohort received 1 and 2 PCT lines before CLM resection (group 1 and 2, respectively). Survival and prognostic factors were analysed. RESULTS: After a mean follow-up of 30.1 months, there was no difference in survival from CLM diagnosis (median, 3-, and 5-year overall survival [OS]: 58.6 months, 76% and 49% in group 2 versus 58.9 months, 71% and 49% in group 1, respectively, P = 0.32). After hepatectomy, disease-free survival (DFS) was however shorter in group 2: 17.2 months, 27% and 15% versus 19.4 months, 32% and 23%, respectively (P = 0.001). Among the initially unresectable patients of group 1 and 2, no statistical difference in OS or DFS was observed. Independent predictors of worse OS in group 2 were positive primary lymph nodes, extrahepatic disease, tumour progression on second line, R2 resection and number of hepatectomies/year <50. Positive primary nodes, synchronous and bilateral metastases were predictors of shorter DFS. Initial unresectability did not impact OS or DFS in group 2. CONCLUSION: CLM resection following second-line PCT, after oncosurgically favourable selection, could bring similar OS compared to what observed after first-line. For initially unresectable patients, OS or DFS is comparable between first- and second-line PCT. Surgery should not be denied after the failure of first-line chemotherapy.
引用
- Adam R, Yi B, Innominato PF, et al. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017. PMID: 28407529. doi:10.1016/j.ejca.2017.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。